

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Tycoon Group Holdings Limited**

**滿貫集團控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3390)**

### **CHANGE OF NON-EXECUTIVE DIRECTOR**

The Board announces that:

- (1) Mr. Hu Yang has resigned as a non-executive director due to work adjustments, such resignation will take effect on 1 July 2025; and
- (2) the Board has resolved to appoint each of Mr. Ng Kwan Ho and Mr. Cao Ran as a non-executive Director with effect from 1 July 2025.

### **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board (“**Board**”) of directors (“**Director(s)**”) of Tycoon Group Holdings Limited (“**Company**”), together with its subsidiaries, the “**Group**”) announces that Mr. Hu Yang (“**Mr. Hu**”) has tendered his resignation as a non-executive director due to work adjustments and such resignation will take effect on 1 July 2025.

Mr. Hu has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) and the shareholders of the Company.

The Board would like to take this opportunity to express its gratitude to Mr. Hu for his valuable contributions to the Company during his tenure as a non-executive Director.

### **APPOINTMENT OF NON-EXECUTIVE DIRECTORS**

The Board is pleased to announce that each of Mr. Ng Kwan Ho (“**Mr. Ng**”) and Mr. Cao Ran (“**Mr. Cao**”) has been appointed as a non-executive Director with effect from 1 July 2025.

The biographical details of Mr. Ng and Mr. Cao are as follows:

**Mr. Ng Kwan Ho**, aged 49, obtained a Bachelor of Arts with Honours Degree in Language Information Science from the City University of Hong Kong in November 1999 and a Master of Philosophy from the City University of Hong Kong in November 2001.

Mr. Ng has extensive experience in marketing, brand management and strategies planning. He worked at Vita Green Health Products Co. Ltd, a company that produces Chinese and Western health supplements with markets in Hong Kong, mainland China, southeast Asia and Europe, from June 2005 to April 2018 with his last position as a marketing director. Mr. Ng subsequently joined Amway Hong Kong Limited, a multinational direct selling company, as a marketing director from May 2018 to October 2022, with his last position as an experience and operation director from November 2022 to July 2024. Since August 2024, he joined JBM (Healthcare) Limited, the issued shares of which are listed on the Main Board of the Stock Exchange (stock code: 2161) and is currently the vice president in brand management and strategies planning.

Save as disclosed above, as at the date of this announcement, Mr. Ng confirmed that he does not (i) have any relationship with any Director, senior management, substantial shareholders or controlling shareholders of the Company; (ii) have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) hold any other positions with the Company or other members of the Group; and (iv) hold any other major appointments or any professional qualifications, or any directorships in other listed companies, the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years.

Pursuant to the letter of appointment entered into between Mr. Ng and the Company, Mr. Ng is appointed as a non-executive Director for a continuous term commencing from 1 July 2025, subject to termination by either Mr. Ng or the Company by one month's prior written notice, unless otherwise such shorter notice consented by the Company. Mr. Ng's appointment is also subject to retirement by rotation and re-election at the annual general meeting in accordance with the articles of association of the Company. Mr. Ng is entitled to an annual remuneration of HK\$180,000, which was determined with reference to his experience, duties, responsibilities, qualifications, the Company's remuneration policy and the prevailing market conditions.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Ng neither needed to be brought to the attention of the shareholders of the Company, nor any other information required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange ("**Listing Rules**").

**Mr. Cao Ran**, aged 42, obtained a bachelor's degree in pharmaceutical engineering from Beijing Union University, the People's Republic of China in July 2005.

Mr. Cao has extensive experience in operations and pharmaceutical production management. From August 2005 to June 2022, Mr. Cao worked at China Resources Double-Crane Pharmaceutical Co., Ltd. (listed on the Shanghai Stock Exchange with stock code 600062), with his last position as a workshop supervisor. Since July 2022, he joined China Resources Pharmaceutical Holdings Company Limited (a wholly-owned subsidiary of China Resources Pharmaceutical Group Limited, stock code: 3320.HK), engaging in production management, operations management, post-investment management etc. He is currently the director of the operations management department of China Resources Pharmaceutical Holdings Company Limited.

Save as disclosed above, as at the date of this announcement, Mr. Cao confirmed that he does not (i) have any relationship with any Director, senior management, substantial shareholders or controlling shareholders of the Company; (ii) have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) hold any other positions with the Company or other members of the Group; and (iv) hold any other major appointments or any professional qualifications, or any directorships in other listed companies, the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years.

Pursuant to the letter of appointment entered into between Mr. Cao and the Company, Mr. Cao is appointed as a non-executive Director for a continuous term commencing from 1 July 2025, subject to termination by either Mr. Cao or the Company by one month's prior written notice, unless otherwise such shorter notice consented by the Company. Mr. Cao's appointment is also subject to retirement by rotation and re-election at the annual general meeting in accordance with the articles of association of the Company. Mr. Cao will not be entitled to receive any director's fee from the Company.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Cao neither needed to be brought to the attention of the shareholders of the Company, nor any other information required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board wishes to express its warmest welcome to Mr. Ng and Mr. Cao for joining the Board.

On behalf of the Board  
**Tycoon Group Holdings Limited**  
**Wong Ka Chun Michael**  
*Chairman, Executive Director  
and Chief Executive Officer*

Hong Kong, 13 June 2025

*As at the date of this announcement, the executive Director is Mr. Wong Ka Chun Michael; the non-executive Directors are Mr. Hu Yang, Ms. Liang Yan, Ms. Li Ka Wa Helen and Mr. Lau Ka On David; and the independent non-executive Directors are Mr. Chung Siu Wah, Ms. Chan Ka Lai Vanessa and Mr. Mak Chung Hong (also known as Mak Tommy Chung Hong).*